Amylyx is developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that target the neuroinflammation and nerve cell death that characterize these disorders. The company\'s therapeutic candidate, AMX0035, is a proprietary, fixed-dose combination therapy that blocks nerve cell death and neurotoxic inflammation.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/23/16 | $5,000,000 | Series A |
ALS Investment Fund Henri Termeer Morningside Venture | undisclosed |
| 07/01/20 | $30,000,000 | Series B |
Morningside Group | undisclosed |
| 07/20/21 | $135,000,000 | Series C |
683 Capital Management aMoon Bain Capital Life Sciences Falcon Edge Capital Marshall Wace Morningside Venture Perceptive Advisors Rock Springs Capital Tybourne Capital Management Verition Fund Management Viking Global Investors Woodline Partners | undisclosed |
